Access the full text.
Sign up today, get DeepDyve free for 14 days.
Minjun Chen, Halil Bisgin, Li Tong, H. Hong, H. Fang, J. Borlak, W. Tong (2014)
Toward predictive models for drug-induced liver injury in humans: are we there yet?Biomarkers in medicine, 8 2
R. Thompson, E. Isin, Yan Li, L. Weidolf, K. Page, I. Wilson, S. Swallow, Brian Middleton, S. Stahl, Alison Foster, H. Dolgos, R. Weaver, J. Kenna (2012)
In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.Chemical research in toxicology, 25 8
Sarah Dawson, S. Stahl, N. Paul, J. Barber, J. Kenna (2012)
In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in HumansDrug Metabolism and Disposition, 40
Toru Usui, M. Mise, T. Hashizume, M. Yabuki, S. Komuro (2009)
Evaluation of the Potential for Drug-Induced Liver Injury Based on in Vitro Covalent Binding to Human Liver ProteinsDrug Metabolism and Disposition, 37
Shintaro Nakayama, R. Atsumi, H. Takakusa, Yoshimasa Kobayashi, A. Kurihara, Y. Nagai, D. Nakai, O. Okazaki (2009)
A Zone Classification System for Risk Assessment of Idiosyncratic Drug Toxicity Using Daily Dose and Covalent BindingDrug Metabolism and Disposition, 37
Stephen Choi (2003)
Nefazodone (Serzone) withdrawn because of hepatotoxicity.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 169 11
F. Shah, S. Louise-May, N. Greene (2014)
Chemotypes sensitivity and predictivity of in vivo outcomes for cytotoxic assays in THLE and HepG2 cell lines.Bioorganic & medicinal chemistry letters, 24 12
(2009)
http://www.bloomberg.com/apps/news?pid1⁄4 newsarchive&sid1⁄4a7yX6S3XPHNQ
M. Aleo, Yi Luo, Rachel Swiss, P. Bonin, D. Potter, Y. Will (2014)
Human drug‐induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pumpHepatology, 60
B. Howell, Yuching Yang, Rukmini Kumar, J. Woodhead, A. Harrill, H. Clewell, M. Andersen, S. Siler, P. Watkins (2012)
In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILIJournal of Pharmacokinetics and Pharmacodynamics, 39
A. Kalliokoski, M. Niemi (2009)
Impact of OATP transporters on pharmacokineticsBritish Journal of Pharmacology, 158
G. Grandi, A. Cagnacci, A. Volpe (2014)
Pharmacokinetic evaluation of desogestrel as a female contraceptiveExpert Opinion on Drug Metabolism & Toxicology, 10
A. Rodrigues, Yurong Lai, M. Cvijic, L. Elkin, T. Zvyaga, M. Soars (2014)
Drug-Induced Perturbations of the Bile Acid Pool, Cholestasis, and Hepatotoxicity: Mechanistic Considerations beyond the Direct Inhibition of the Bile Salt Export PumpDrug Metabolism and Disposition, 42
Minjun Chen, V. Vijay, Q. Shi, Zhichao Liu, H. Fang, W. Tong (2011)
FDA-approved drug labeling for the study of drug-induced liver injury.Drug discovery today, 16 15-16
B. Feng, J. Xu, Y. Bi, Rouchelle Mireles, Ralph Davidson, D. Duignan, S. Campbell, V. Kostrubsky, M. Dunn, A.R. Smith, Huifen Wang (2009)
Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.Toxicological sciences : an official journal of the Society of Toxicology, 108 2
R. Obach, F. Lombardo, N. Waters (2008)
Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 670 Drug CompoundsDrug Metabolism and Disposition, 36
E. Leifke, H. Naik, J. Wu, P. Viswanathan, D. Demanno, M. Kipnes, M. Vakilynejad (2012)
A Multiple‐Ascending‐Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK‐875, in Subjects With Type 2 DiabetesClinical Pharmacology & Therapeutics, 92
B. Fromenty, D. Pessayre (1995)
Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity.Pharmacology & therapeutics, 67 1
T. Kakuda (2000)
Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.Clinical therapeutics, 22 6
J. Hoofnagle, J. Serrano, J. Knoben, V. Navarro (2013)
LiverTox: A website on drug‐induced liver injuryHepatology, 57
J. Xu, Peter Henstock, M. Dunn, A.R. Smith, Jeffrey Chabot, D. Graaf (2008)
Cellular imaging predictions of clinical drug-induced liver injury.Toxicological sciences : an official journal of the Society of Toxicology, 105 1
N. Greene, M. Aleo, S. Louise-May, David Price, Y. Will (2010)
Using an in vitro cytotoxicity assay to aid in compound selection for in vivo safety studies.Bioorganic & medicinal chemistry letters, 20 17
Ryan Morgan, M. Trauner, C. Staden, Paul Lee, B. Ramachandran, M. Eschenberg, C. Afshari, C. Qualls, Ruth Lightfoot-Dunn, H. Hamadeh (2010)
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.Toxicological sciences : an official journal of the Society of Toxicology, 118 2
H. Olson, G. Betton, D. Robinson, K. Thomas, A. Monro, G. Kolaja, P. Lilly, James Sanders, Glenn Sipes, W. Bracken, M. Dorato, Koen Deun, Peter Smith, B. Berger, Allen Heller (2000)
Concordance of the toxicity of pharmaceuticals in humans and in animals.Regulatory toxicology and pharmacology : RTP, 32 1
Travis Wager, B. Kormos, Joseph Brady, Y. Will, M. Aleo, D. Stedman, Max Kuhn, R. Chandrasekaran (2013)
Improving the odds of success in drug discovery: choosing the best compounds for in vivo toxicology studies.Journal of medicinal chemistry, 56 23
A. Stepan, Daniel Walker, J. Bauman, David Price, T. Baillie, A. Kalgutkar, M. Aleo (2011)
Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States.Chemical research in toxicology, 24 9
C. Lammert, S. Einarsson, C. Saha, A. Niklasson, E. Bjornsson, N. Chalasani (2008)
Relationship between daily dose of oral medications and idiosyncratic drug‐induced liver injury: Search for signalsHepatology, 47
M. Porceddu, N. Buron, C. Roussel, G. Labbe, B. Fromenty, A. Borgne-Sanchez (2012)
Prediction of Liver Injury Induced by Chemicals in Human With a Multiparametric Assay on Isolated Mouse Liver MitochondriaToxicological Sciences, 129
P. O'Brien, William Irwin, D. Díaz, E. Howard-Cofield, C. Krejsa, M. Slaughter, B. Gao, N. Kaludercic, A. Angeline, P. Bernardi, P. Brain, C. Hougham (2006)
High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screeningArchives of Toxicology, 80
N. Greene, Minghu Song (2011)
Predicting in vivo safety characteristics using physiochemical properties and in vitro assays.Future medicinal chemistry, 3 12
Ryan Morgan, C. Staden, Yuan Chen, Nataraj Kalyanaraman, Jackson Kalanzi, R. Dunn, C. Afshari, H. Hamadeh (2013)
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, 136 1
J. Woodhead, Kyunghee Yang, S. Siler, P. Watkins, K. Brouwer, H. Barton, B. Howell (2014)
Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injuryFrontiers in Pharmacology, 5
Minjun Chen, J. Borlak, W. Tong (2013)
High lipophilicity and high daily dose of oral medications are associated with significant risk for drug‐induced liver injuryHepatology, 58
(2011)
Inhibition of glucagon-induced hyperglycemia predicts glucose lowering efficacy of a glucagon receptor antagonist, MK-0893
Minjun Chen, H. Hong, H. Fang, Reagan Kelly, Guangxu Zhou, J. Borlak, W. Tong (2013)
Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs.Toxicological sciences : an official journal of the Society of Toxicology, 136 1
J. Hynes, S. Nadanaciva, Rachel Swiss, C. Carey, Sinead Kirwan, Y. Will (2013)
A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays.Toxicology in vitro : an international journal published in association with BIBRA, 27 2
Seva Kostrubsky, S. Strom, A. Kalgutkar, Shaila Kulkarni, J. Atherton, Rouchelle Mireles, B. Feng, Raylene Kubik, Janean Hanson, E. Urda, A. Mutlib (2006)
Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone.Toxicological sciences : an official journal of the Society of Toxicology, 90 2
F. Shah, N. Greene (2014)
Analysis of Pfizer compounds in EPA's ToxCast chemicals-assay space.Chemical research in toxicology, 27 1
Kyunghee Yang, J. Woodhead, P. Watkins, B. Howell, K. Brouwer (2014)
Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid-Mediated Troglitazone HepatotoxicityClinical pharmacology and therapeutics, 96
Michael Holt, C. Ju (2010)
Drug-induced liver injury.Handbook of experimental pharmacology, 196
R. Kelly, P. Garhyan, E. Raddad, H. Fu, C. Lim, M. Prince, J. Pinaire, M. Loh, M. Deeg (2015)
Short‐term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetesDiabetes, 17
Lisa Marroquin, J. Hynes, J. Dykens, J. Jamieson, Y. Will (2007)
Circumventing the Crabtree effect: replacing media glucose with galactose increases susceptibility of HepG2 cells to mitochondrial toxicants.Toxicological sciences : an official journal of the Society of Toxicology, 97 2
R. Roth, P. Ganey (2010)
Intrinsic versus Idiosyncratic Drug-Induced Hepatotoxicity—Two Villains or One?Journal of Pharmacology and Experimental Therapeutics, 332
J. Hynes, Lisa Marroquin, V. Ogurtsov, K. Christiansen, G. Stevens, D. Papkovsky, Y. Will (2006)
Investigation of drug-induced mitochondrial toxicity using fluorescence-based oxygen-sensitive probes.Toxicological sciences : an official journal of the Society of Toxicology, 92 1
Mhairi Greer, T. Smith, J. Kenna (2009)
Mechanisms of Drug Hepatotoxicity in Man: Novel Insights Provided by the THLE-CYP Cell PanelToxicology, 262
Yvonne Meier, C. Pauli-Magnus, U. Zanger, K. Klein, E. Schaeffeler, A. Nussler, N. Nussler, M. Eichelbaum, P. Meier, B. Stieger (2006)
Interindividual variability of canalicular ATP‐binding‐cassette (ABC)–transporter expression in human liverHepatology, 44
Y. Shitara, K. Maeda, Kazuaki Ikejiri, Kenta Yoshida, T. Horie, Y. Sugiyama (2013)
Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption.Biopharmaceutics & drug disposition, 34 1
Eun-Woo Lee, Yurong Lai, Huixia Zhang, J. Unadkat (2006)
Identification of the Mitochondrial Targeting Signal of the Human Equilibrative Nucleoside Transporter 1 (hENT1)Journal of Biological Chemistry, 281
Severe drug-induced liver injury (DILI) remains a major safety issue due to its frequency of occurrence, idiosyncratic nature, poor prognosis, and diverse underlying mechanisms. Numerous experimental approaches have been published to improve human DILI prediction with modest success. A retrospective analysis of 125 drugs (70most-DILI, 55no-DILI) from the Food and Drug Administration Liver Toxicity Knowledge Base was used to investigate DILI prediction based on consideration of human exposure alone or in combination with mechanistic assays of hepatotoxic liabilities (cytotoxicity, bile salt export pump inhibition, or mitochondrial inhibition/uncoupling). Using this dataset, human plasma Cmax,total1.1M alone distinguished most-DILI from no-DILI compounds with high sensitivity/specificity (80/73). Accounting for human exposure improved the sensitivity/specificity for each assay and helped to derive predictive safety margins. Compounds with plasma Cmax,total1.1M and triple liabilities had significantly higher odds ratio for DILI than those with single/dual liabilities. Using this approach, a subset of recent pharmaceuticals with evidence of liver injury during clinical development was recognized as potential hepatotoxicants. In summary, plasma Cmax,total1.1M along with multiple mechanistic liabilities is a major driver for predictions of human DILI potential. In applying this approach during drug development the challenge will be generating accurate estimates of plasma Cmax,total at efficacious doses in advance of generating true exposure data from clinical studies. In the meantime, drug candidates with multiple hepatotoxic liabilities should be deprioritized, since they have the highest likelihood of causing DILI in case their efficacious plasma Cmax,total in humans is higher than anticipated.
Toxicological Sciences – Oxford University Press
Published: Oct 23, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.